Agendia to Collaborate with MD Anderson, Netherlands Institute to Further Validate ColoPrint

"We will use multiple 'omics' technologies to ask which kinase signaling pathways are activated in colon cancer," an Agendia spokesperson said of the collaboration, which will also provide independent validation of the company's ColoPrint colon cancer recurrence test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.